| 1 | 
                
                    DHFR
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142 
                
                    D00142
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 2 | 
                
                    DHFR
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115 
                
                    D02115
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 3 | 
                
                    DHODH
                
             | 3件:  Pyrimidine metabolism Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors | D00749 
                
                    D00749
                
             | 
                
                    Leflunomide
                
             | 12件:  11 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 | 
| 4 | 
                
                    DHFR2
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142 
                
                    D00142
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 5 | 
                
                    DHFR2
                
             | 5件:  One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115 
                
                    D02115
                
             | 
                
                    Methotrexate
                
             | 38件:  11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 | 
| 6 | 
                
                    FCER1A
                
             | 4件:  Sphingolipid signaling pathway Sphingolipid signaling pathway, Phospholipase D signaling pathway, Fc epsilon RI signaling pathway, Asthma | D05251 
                
                    D05251
                
             | 
                
                    Omalizumab
                
             | 7件:  46 46, 53, 65, 98, 162, 226, 299 | 
| 7 | 
                
                    ABL1
                
             | 11件:  ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D01441 
                
                    D01441
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 8 | 
                
                    ABL1
                
             | 11件:  ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08066 
                
                    D08066
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 9 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292 
                
                    D00292
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 10 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00385 
                
                    D00385
                
             | 
                
                    Triamcinolone
                
             | 3件:  162 162, 226, 298 | 
| 11 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407 
                
                    D00407
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 12 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472 
                
                    D00472
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 13 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473 
                
                    D00473
                
             | 
                
                    Prednisone
                
             | 14件:  162 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | 
| 14 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00690 
                
                    D00690
                
             | 
                
                    Mometasone
                
             | 1件:  162 162 | 
| 15 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00690 
                
                    D00690
                
             | 
                
                    Mometasone furoate
                
             | 1件:  162 162 | 
| 16 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00751 
                
                    D00751
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 17 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00975 
                
                    D00975
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 18 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00979 
                
                    D00979
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 19 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00980 
                
                    D00980
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 20 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00981 
                
                    D00981
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 21 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00982 
                
                    D00982
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 22 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00983 
                
                    D00983
                
             | 
                
                    Triamcinolone
                
             | 3件:  162 162, 226, 298 | 
| 23 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00984 
                
                    D00984
                
             | 
                
                    Triamcinolone
                
             | 3件:  162 162, 226, 298 | 
| 24 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00985 
                
                    D00985
                
             | 
                
                    Triamcinolone
                
             | 3件:  162 162, 226, 298 | 
| 25 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01239 
                
                    D01239
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 26 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01272 
                
                    D01272
                
             | 
                
                    Clobetasol propionate
                
             | 1件:  162 162 | 
| 27 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01510 
                
                    D01510
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 28 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01615 
                
                    D01615
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 29 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01632 
                
                    D01632
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 30 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01948 
                
                    D01948
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 31 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01998 
                
                    D01998
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 32 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02156 
                
                    D02156
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 33 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02174 
                
                    D02174
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 34 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02591 
                
                    D02591
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 35 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02592 
                
                    D02592
                
             | 
                
                    Dexamethasone
                
             | 7件:  162 162, 222, 235, 257, 283, 296, 299 | 
| 36 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03301 
                
                    D03301
                
             | 
                
                    Prednisolone
                
             | 8件:  162 162, 222, 269, 271, 296, 299, 300, 307 | 
| 37 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03325 
                
                    D03325
                
             | 
                
                    Mometasone
                
             | 1件:  162 162 | 
| 38 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000 
                
                    D05000
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 39 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05001 
                
                    D05001
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 40 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05002 
                
                    D05002
                
             | 
                
                    Methylprednisolone
                
             | 12件:  162 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 | 
| 41 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D06216 
                
                    D06216
                
             | 
                
                    Triamcinolone
                
             | 3件:  162 162, 226, 298 | 
| 42 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07202 
                
                    D07202
                
             | 
                
                    Halometasone
                
             | 1件:  162 162 | 
| 43 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07715 
                
                    D07715
                
             | 
                
                    Clobetasol propionate
                
             | 1件:  162 162 | 
| 44 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07715 
                
                    D07715
                
             | 
                
                    Clobetasol
                
             | 1件:  162 162 | 
| 45 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08227 
                
                    D08227
                
             | 
                
                    Mometasone
                
             | 1件:  162 162 | 
| 46 | 
                
                    NR3C1
                
             | 1件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08416 
                
                    D08416
                
             | 
                
                    Prednisone acetate
                
             | 2件:  162 162, 224 | 
| 47 | 
                
                    HMGCR
                
             | 4件:  Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D00434 
                
                    D00434
                
             | 
                
                    Simvastatin
                
             | 21件:  6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 | 
| 48 | 
                
                    IL4R
                
             | 8件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D10354 
                
                    D10354
                
             | 
                
                    Dupilumab
                
             | 4件:  51 51, 98, 160, 162 | 
| 49 | 
                
                    IL5
                
             | 13件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | D04923 
                
                    D04923
                
             | 
                
                    Mepolizumab
                
             | 4件:  44 44, 45, 98, 162 | 
| 50 | 
                
                    IL5RA
                
             | 4件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09874 
                
                    D09874
                
             | 
                
                    Benralizumab
                
             | 5件:  44 44, 45, 98, 162, 299 | 
| 51 | 
                
                    IL12A
                
             | 25件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214 
                
                    D09214
                
             | 
                
                    Ustekinumab
                
             | 17件:  37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 | 
| 52 | 
                
                    IL12B
                
             | 25件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214 
                
                    D09214
                
             | 
                
                    Ustekinumab
                
             | 17件:  37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 | 
| 53 | 
                
                    IL17A
                
             | 6件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D10071 
                
                    D10071
                
             | 
                
                    Ixekizumab
                
             | 6件:  36 36, 37, 107, 162, 269, 271 | 
| 54 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752 
                
                    D00752
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 55 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094 
                
                    D05094
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 56 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095 
                
                    D05095
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 57 | 
                
                    IMPDH1
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096 
                
                    D05096
                
             | 
                
                    Mycophenolic acid
                
             | 36件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | 
| 58 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752 
                
                    D00752
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 59 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094 
                
                    D05094
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 60 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095 
                
                    D05095
                
             | 
                
                    Mycophenolate mofetil
                
             | 34件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | 
| 61 | 
                
                    IMPDH2
                
             | 3件:  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096 
                
                    D05096
                
             | 
                
                    Mycophenolic acid
                
             | 36件:  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | 
| 62 | 
                
                    JAK1
                
             | 27件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10308 
                
                    D10308
                
             | 
                
                    Baricitinib
                
             | 13件:  41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 | 
| 63 | 
                
                    JAK2
                
             | 24件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10308 
                
                    D10308
                
             | 
                
                    Baricitinib
                
             | 13件:  41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 | 
| 64 | 
                
                    KIT
                
             | 11件:  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D01441 
                
                    D01441
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 65 | 
                
                    KIT
                
             | 11件:  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08066 
                
                    D08066
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 66 | 
                
                    PDE4A
                
             | 5件:  Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860 
                
                    D08860
                
             | 
                
                    Apremilast
                
             | 7件:  46 46, 50, 56, 97, 107, 162, 271 | 
| 67 | 
                
                    PDE4B
                
             | 5件:  Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860 
                
                    D08860
                
             | 
                
                    Apremilast
                
             | 7件:  46 46, 50, 56, 97, 107, 162, 271 | 
| 68 | 
                
                    PDE4C
                
             | 5件:  Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860 
                
                    D08860
                
             | 
                
                    Apremilast
                
             | 7件:  46 46, 50, 56, 97, 107, 162, 271 | 
| 69 | 
                
                    PDE4D
                
             | 5件:  Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860 
                
                    D08860
                
             | 
                
                    Apremilast
                
             | 7件:  46 46, 50, 56, 97, 107, 162, 271 | 
| 70 | 
                
                    IL23A
                
             | 9件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09214 
                
                    D09214
                
             | 
                
                    Ustekinumab
                
             | 17件:  37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 | 
| 71 | 
                
                    IL23A
                
             | 9件:  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10400 
                
                    D10400
                
             | 
                
                    Tildrakizumab
                
             | 2件:  162 162, 271 | 
| 72 | 
                
                    PDGFRA
                
             | 20件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D01441 
                
                    D01441
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 73 | 
                
                    PDGFRA
                
             | 20件:  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08066 
                
                    D08066
                
             | 
                
                    Imatinib
                
             | 12件:  13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 | 
| 74 | 
                
                    PPP3CA
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 75 | 
                
                    PPP3CB
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 76 | 
                
                    PPP3CC
                
             | 33件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 77 | 
                
                    PPP3R1
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 78 | 
                
                    PPP3R2
                
             | 32件:  MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184 
                
                    D00184
                
             | 
                
                    Cyclosporine
                
             | 44件:  11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | 
| 79 | 
                
                    TNF
                
             | 67件:  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598 
                
                    D02598
                
             | 
                
                    Infliximab
                
             | 27件:  35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 | 
| 80 | 
                
                    C5
                
             | 10件:  Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11473 
                
                    D11473
                
             | 
                
                    Nomacopan
                
             | 3件:  62 62, 109, 162 | 
| 81 | 
                
                    VDR
                
             | 5件:  Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188 
                
                    D00188
                
             | 
                
                    Cholecalciferol
                
             | 25件:  6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 | 
| 82 | 
                
                    MS4A1
                
             | 1件:  Hematopoietic cell lineage Hematopoietic cell lineage | D02994 
                
                    D02994
                
             | 
                
                    Rituximab
                
             | 13件:  162 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |